Literature DB >> 7506235

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.

B Huard1, P Gaulard, F Faure, T Hercend, F Triebel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7506235     DOI： 10.1007/bf00241263

Source DB:  PubMed          Journal:  Immunogenetics        ISSN： 0093-7711            Impact factor:   2.846


× No keyword cloud information.
  4 in total

1.  An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein.

Authors:  S C Meuer; R E Hussey; M Fabbi; D Fox; O Acuto; K A Fitzgerald; J C Hodgdon; J P Protentis; S F Schlossman; E L Reinherz
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

2.  Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.

Authors:  B Escudier; F Farace; E Angevin; F Triebel; S Antoun; B Leclercq; M Brandely; A Aboudaram; G Nitenberg; T Hercend
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

3.  LAG-3, a novel lymphocyte activation gene closely related to CD4.

Authors:  F Triebel; S Jitsukawa; E Baixeras; S Roman-Roman; C Genevee; E Viegas-Pequignot; T Hercend
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

4.  Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.

Authors:  E Baixeras; B Huard; C Miossec; S Jitsukawa; M Martin; T Hercend; C Auffray; F Triebel; D Piatier-Tonneau
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307
  4 in total
  60 in total

Review 1.  Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.

Authors:  Rajarsi Mandal; Timothy A Chan
Journal:  Cancer Discov       Date:  2016-04-22       Impact factor: 39.397

2.  LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.

Authors:  Sandrine Buisson; Frédéric Triebel
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 3.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

4.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

Review 5.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 6.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

Review 7.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 8.  Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.

Authors:  Yara Abdou; Manu Pandey; Maithreyi Sarma; Shrunjal Shah; Jeffrey Baron; Marc S Ernstoff
Journal:  Br J Clin Pharmacol       Date:  2020-05-12       Impact factor: 4.335

9.  Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4.

Authors:  Seng-Ryong Woo; Nianyu Li; Tullia C Bruno; Karen Forbes; Scott Brown; Creg Workman; Charles G Drake; Dario A A Vignali
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

Review 10.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.